Passage Bio scraps a therapy; XOMA’s new loan; Impel is for sale

Plus, news on ImpriMed, bluebird bio and Syndax.

Passage Bio shakes up its pipeline: The Jim Wilson-founded biotech is shelving a therapy for GM1 gangliosidosis. It now plans to focus on a preclinical Huntington’s gene therapy and a gene therapy for patients with a form of…
Click here to view original post